Company Description
ASP Isotopes Inc., a development stage advanced materials company, engages in the production, distribution, marketing, and sale of isotopes.
It operates in two segments, Nuclear Fuels and Specialist Isotopes and Related Services. The Nuclear Fuels segment focuses on the research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market.
Its Specialist Isotopes and Related Services segment engages in the research and development of technologies and methods used to separate high-value, low-volume isotopes, such as C-14, Mo-100 and Si-28, for target end markets, including pharmaceuticals and agrochemicals, nuclear medical imaging, and semiconductors; provision of related services; and operation of PET labs.
The company offers the Aerodynamic Separation Process (ASP) technology, which separates gas species and isotopes in a volatile state; and the Quantum Enrichment (QE) technology, which selectively ionizes and separates isotopes.
It also produces and commercializes Molybdenum-100, Molybdenum-98, and Ytterbium-176 for the nuclear medical industry; Silicon-28, which is used in semiconductors; and Carbon-14 for pharmaceuticals and agrochemicals.
In addition, the company develops Zinc-67/68, Nickel-68, and Xenon 129/136 for the nuclear medical industry; Lithium-6, Lithium-7, Uranium-235, Chlorine-37, and Thorium Fluoride for the energy industry; and Germanium-70/72/74.
ASP Isotopes Inc. was incorporated in 2021 and is headquartered in Washington, District Of Columbia.
| Country | United States |
| Founded | 2021 |
| IPO Date | Nov 10, 2022 |
| Industry | Chemicals |
| Sector | Materials |
| Employees | 136 |
| CEO | Paul Mann |
Contact Details
Address: 601 Pennsylvania Avenue NW, Suite 900 Washington, District of Columbia 20004 United States | |
| Phone | 202 756 2245 |
| Website | aspisotopes.com |
Stock Details
| Ticker Symbol | ASPI |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 0001921865 |
| CUSIP Number | 00218A105 |
| ISIN Number | US00218A1051 |
| Employer ID | 87-2618235 |
| SIC Code | 2890 |
Key Executives
| Name | Position |
|---|---|
| Dr. Gerdus Kemp M.D., Ph.D. | Medical Director and Chief Executive Officer of Pet Labs |
| Paul Elliot Mann C.F.A. | President, Chief Executive Officer and Executive Chairman |
| Heather Kiessling | Chief Financial Officer |
| Robert Ainscow | Chief Operating Officer |
| Dr. Hendrik Strydom B. Sc, M. Sc, Ph.D. | Chief Technology Officer |
| William Eden M.B.E. | Global Head of Human Resources and Director UK Nuclear Operations |
| Hendrik T. van Wyk | Head of Engineering |
| Dr. Xandra van Heerden Ph.D. | Head of Research and Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 30, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Apr 30, 2025 | 10-K/A | [Amend] Annual report |
| Apr 15, 2025 | 144 | Filing |
| Apr 15, 2025 | 144 | Filing |
| Apr 15, 2025 | 8-K | Current Report |
| Apr 11, 2025 | SCHEDULE 13G | Filing |
| Apr 9, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 1, 2025 | 8-K | Current Report |
| Mar 31, 2025 | 10-K | Annual Report |
| Mar 31, 2025 | 8-K | Current Report |